{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-men/prescribing-information/nitrofurantoin/","result":{"pageContext":{"chapter":{"id":"675b98e1-e1fa-59e0-89d1-0558968a78ba","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin","depth":2,"htmlHeader":"<!-- begin field 760a7a90-2e95-42f7-bf29-d5c42e5ab42a --><h2>Nitrofurantoin</h2><!-- end field 760a7a90-2e95-42f7-bf29-d5c42e5ab42a -->","summary":"","htmlStringContent":"<!-- begin item a2eeb596-eb5a-414c-b10d-5cc564dd4335 --><!-- end item a2eeb596-eb5a-414c-b10d-5cc564dd4335 -->","topic":{"id":"335f7066-6009-52c3-bb1e-bb68e732e41f","topicId":"933b760e-86fa-4ba1-b937-3c052be97e83","topicName":"Urinary tract infection (lower) - men","slug":"urinary-tract-infection-lower-men","lastRevised":"Last revised in November 2018","chapters":[{"id":"a1f0f874-afae-5abc-bfc0-b8aff4687b8d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"722a30e1-802e-50da-aeb2-55a320f811e0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"54bfd7d0-4d24-5c97-b344-6dc7fe0500bf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d780254d-b3a6-5120-a061-adbfa9d6c3d3","slug":"changes","fullItemName":"Changes"},{"id":"ded6008d-05b8-54a3-9be7-e1f9c635b466","slug":"update","fullItemName":"Update"}]},{"id":"281305b2-29ee-5ee3-879d-2a1c6115b107","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"28ce53d8-a9de-582e-b21f-63a49c9518b7","slug":"goals","fullItemName":"Goals"},{"id":"80a08351-02e8-5bf8-9865-b1f745f759f9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c65e1ea0-2e57-5742-8d13-e19bbdabcf5b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7c3a6d64-9cf2-5b7f-8c66-ac2aa0dab8b9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edc3c38c-1e69-5da3-8da7-174dd323fee3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a235fb13-94fa-5fa1-ac15-eae46288950c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f1cf9c73-1a32-5912-8f20-a511a2baa05c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"423dc347-3ec3-514e-bd33-486d46645934","slug":"definition","fullItemName":"Definition"},{"id":"57c35511-4b16-5330-9634-f12fd1accf63","slug":"causes","fullItemName":"Causes"},{"id":"479b7fa1-3b50-51c3-89ac-1373a3aec46a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c6d01476-282e-5662-8378-40f864eedc0e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc3e67c4-09a3-557a-b9d1-7bd1b9692fd3","slug":"complications","fullItemName":"Complications"}]},{"id":"a4c4a87e-e501-53b8-bdd5-15185f853016","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"61ab2e56-53dc-5875-a0bc-41dc08a4b6b8","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"3f5567ff-0ab4-5228-80d9-6b8addad17e0","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"e65bf3d7-aefc-572c-bf7b-6eb6573d7fb6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"923818be-e371-5af0-91a7-c470d34dac3c","fullItemName":"Management","slug":"management","subChapters":[{"id":"e3d61967-efe7-54fc-acbd-2e51935ca714","slug":"lower-uti-in-men","fullItemName":"Scenario: Lower UTI in men"},{"id":"f0357d1a-f5ca-5139-ac96-98e285b29c36","slug":"recurrent-uti-in-men","fullItemName":"Scenario: Recurrent UTI in men"},{"id":"88bc8e33-1e01-5b50-b9c2-362bd372238f","slug":"uti-in-men-with-an-indwelling-catheter","fullItemName":"Scenario: UTI in men with an indwelling catheter"}]},{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0998f6ff-17aa-58cd-8188-2fe8d30e2a63","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"0b85e5c6-7cc0-58a2-8889-5c211efc01d6","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"675b98e1-e1fa-59e0-89d1-0558968a78ba","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"926ae109-9068-515c-a20f-c9cc8b27eb3b","slug":"pivmecillinam","fullItemName":"Pivmecillinam"}]},{"id":"29b9ddff-7312-54b1-9eae-eefca43a368d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"463fe0f7-80e5-5fcd-9f1c-9c1f76f10f30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a4e1c5ad-c809-5d8c-ae1c-d37b4f97dd8c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ac4b6d54-2a63-5545-ad06-0abbe7f6354e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b0a3ea0-682b-5ab3-ae72-bdc7fd586fce","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f7d5ea54-f1b1-59b5-9856-d52f1d73534a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f847f977-daef-5c70-8aa1-eeaf86d9cce7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"235f01e6-f3e2-5784-a197-3b4a11d45527","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b9067c2e-fc65-5147-b4dc-dd382c9fef9b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b201b8f7-011b-4c4f-b4af-a99800a0a148 --><h3>Contraindications and cautions</h3><!-- end field b201b8f7-011b-4c4f-b4af-a99800a0a148 -->","summary":"","htmlStringContent":"<!-- begin item adf83a23-b799-4f05-a899-a99800a0a05c --><!-- begin field 01732fa4-ab1f-4345-85a9-a99800a0a148 --><ul><li><strong>Do not prescribe nitrofurantoin in infants aged less than 3 months, or people with:</strong><ul><li>Acute porphyria.</li><li>Renal impairment — estimated glomerular filtration rate (eGFR) less than 45 mL/minute/1.73 m<sup>2</sup>.<ul><li>A short course of up to 7 days may be used if the eGFR is 30–44 mL/minute/1.73 m<sup>2</sup> and a urinary tract infection has suspected or proven multi-drug resistance, when the benefits of nitrofurantoin are considered to outweigh the risks of adverse effects.</li></ul></li><li>Glucose-6-phosphate dehydrogenase deficiency.</li></ul></li><li><strong>Prescribe nitrofurantoin with caution in people with:</strong><ul><li>Peripheral neuropathy or susceptibility to peripheral neuropathy —<strong> </strong>treatment should be stopped at the first signs of neural involvement (paraesthesiae).</li><li>Anaemia, diabetes mellitus, electrolyte imbalance, debilitating conditions, and vitamin B (particularly folate).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>] </p><!-- end field 01732fa4-ab1f-4345-85a9-a99800a0a148 --><!-- end item adf83a23-b799-4f05-a899-a99800a0a05c -->","subChapters":[]},{"id":"8e605c8b-1bf8-59c7-a6fa-6c5038431a9f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field eb213477-24de-4338-92bc-a99800a18b26 --><h3>Adverse effects</h3><!-- end field eb213477-24de-4338-92bc-a99800a18b26 -->","summary":"","htmlStringContent":"<!-- begin item 1b789ffa-64b7-4c5a-bfc5-a99800a18af3 --><!-- begin field 76d939a7-3f3a-4701-b56d-a99800a18b26 --><ul><li><strong>Blood disorders</strong> — agranulocytosis, leukopenia, granulocytopenia, haemolytic anaemia, thrombocytopenia, megaloblastic anaemia, glucose-6-phosphate dehydrogenase deficiency anaemia, and eosinophilia (frequency unknown).<ul><li><strong>Rarely: </strong>aplastic anaemia. </li></ul></li><li><strong>Gastrointestinal </strong>— nausea, anorexia, vomiting, abdominal pain, and diarrhoea (frequency unknown).</li><li><strong>Hepatobiliary disorders </strong>— chronic hepatitis, cholestatic jaundice (frequency unknown).</li><li><strong>Respiratory </strong>— acute pulmonary reactions may occur within the first week of treatment, and are manifested by: fever, chills, cough, chest pain, dyspnoea, and eosinophilia. Reversible on stopping treatment.<ul><li><strong>Rarely:</strong> chronic pulmonary reactions occur in people who have received continuous therapy for six months or longer. It is more common in the elderly.</li></ul></li><li><strong>Nervous system </strong>— peripheral neuropathy, nystagmus, vertigo, dizziness, asthenia, headache and drowsiness (frequency unknown).</li><li><strong>Psychiatric disorders </strong>— depression, euphoria, confusion, psychotic reactions (frequency unknown).</li><li><strong>Skin </strong>— angioneurotic oedema, maculopapular, erythematous or eczematous eruptions, urticaria, rash, pruritus,<strong> </strong>lupus-like syndrome, exfoliative dermatitis and erythema multiforme (including Stevens-Johnson Syndrome).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>] </p><!-- end field 76d939a7-3f3a-4701-b56d-a99800a18b26 --><!-- end item 1b789ffa-64b7-4c5a-bfc5-a99800a18af3 -->","subChapters":[]},{"id":"1fe35b04-6567-55af-bf99-ab1d694c13f0","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b3f463b6-348a-44d6-8717-a99800a1a790 --><h3>Drug interactions</h3><!-- end field b3f463b6-348a-44d6-8717-a99800a1a790 -->","summary":"","htmlStringContent":"<!-- begin item a0359ce1-9a2c-400b-a8e6-a99800a1a756 --><!-- begin field 5af63094-a613-45e0-b0ce-a99800a1a790 --><ul><li><strong>Alkalinizing agents (such as potassium citrate)</strong> — the antibacterial activity of nitrofurantoin is reduced when the pH of the urine is increased. It may be prudent to avoid in people taking nitrofurantoin, however there is no evidence that this possible interaction presents a problem in practice.</li><li><strong>Magnesium trisilicate</strong> — absorption of nitrofurantoin may be reduced.  </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>] </p><!-- end field 5af63094-a613-45e0-b0ce-a99800a1a790 --><!-- end item a0359ce1-9a2c-400b-a8e6-a99800a1a756 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}